This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis (NVS) Q3 Earnings Beat, Sandoz Under Strategic Review
by Zacks Equity Research
Novartis (NVS) reports mixed results in the third quarter, as key brands maintain momentum but generics business remains weak.
Regeneron (REGN) Dupixent Meets Goal in Prurigo Nodularis Study
by Zacks Equity Research
Regeneron's (REGN) phase III study on Dupixent for treating adults with uncontrolled prurigo nodularis meets its primary and all secondary endpoints.
The Zacks Analyst Blog Highlights: Alphabet, Netflix, Thermo Fisher Scientific, Wells Fargo and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Netflix, Thermo Fisher Scientific, Wells Fargo and Novartis
Top Stock Reports for Alphabet, Netflix & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Netflix, Inc. (NFLX), and Thermo Fisher Scientific Inc. (TMO).
Deciphera (DCPH) Thrives on Qinlock, Overdependence a Woe
by Zacks Equity Research
Deciphera's (DCPH) Qinlock is approved for treating advanced gastrointestinal stromal tumors. The drug has seen solid uptake since its launch. Heavy dependence on Qinlock for growth remains a concern.
bluebird (BLUE) Gives Details on Oncology Business Spinoff
by Zacks Equity Research
bluebird (BLUE) provides information on stock distribution ratio and cash allocation for the planned spin-off of the oncology business.
Gilead (GILD) Tecartus Gets FDA Nod for Leukemia Indication
by Zacks Equity Research
Following FDA approval, Gilead's (GILD) Tecartus becomes the first and only CAR T-cell therapy approved for treating relapsed/refractory B-cell acute lymphoblastic leukemia in adult patients.
Gilead (GILD) Files sBLA to FDA for Yescarta Label Expansion
by Zacks Equity Research
Gilead's (GILD) wholly owned subsidiary, Kite, submits an sBLA to the FDA for Yescarta to treat relapsed/refractory large B-cell lymphoma in the second-line setting.
Incyte (INCY) Collaborates With Syndax for Chronic GVHD Candidate
by Zacks Equity Research
Incyte (INCY) collaborates with Syndax to develop and commercialize axatilimab for chronic graft-versus-host disease and other fibrotic diseases.
Amgen (AMGN) Repatha Gets FDA Nod for Expanded Use in Kids
by Zacks Equity Research
FDA approves Amgen's (AMGN) Repatha for pediatric patients, 10 years of age and older, with familial hypercholesterolemia, both heterozygous and homozygous forms.
Pharma Stock Roundup: PFE Booster Jab Gets FDA Nod, JNJ's New Data on COVID-19 Shot
by Kinjel Shah
FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine.
Incyte (INCY) Jakafi Wins FDA Approval for Chronic GVHD
by Zacks Equity Research
Incyte's (INCY) going gets good with another FDA approval - Jakafi for the treatment of chronic GVHD. However, the stock witnesses a decline despite the recent approvals.
The Zacks Analyst Blog Highlights: Facebook, Walmart, Novartis, PayPal and Advanced Micro Devices
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Walmart, Novartis, PayPal and Advanced Micro Devices
Top Research Reports for Facebook, Walmart & Novartis
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), Walmart Inc. (WMT), and Novartis AG (NVS).
BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma
by Zacks Equity Research
The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study
by Zacks Equity Research
Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.
BeiGene's (BGNE) BLA for Tislelizumab in ESCC Accepted by FDA
by Zacks Equity Research
The FDA accepts for review BeiGene's (BGNE) BLA for tislelizumab to treat patients with locally advanced/metastatic esophageal squamous cell carcinoma after prior systemic therapy.
FDA Orders Warnings on Pfizer, Lilly, AbbVie JAK Drug Labels
by Kinjel Shah
The FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz/Xeljanz XR, Lilly (LLY)/Incyte's (INCY) Olumiant, and AbbVie's (ABBV) Rinvoq.
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe
by Zacks Equity Research
Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The drug has seen solid uptake since its launch. However, sole dependence on Oxbryta for growth remains a concern.
Top Analyst Reports for Pfizer, AT&T & Intuit
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), AT&T Inc. (T), and Intuit Inc. (INTU).
Pharma Stock Roundup: PFE's COVID Jab Full Approval by FDA, JNJ's Booster Data
by Kinjel Shah
FDA approves Pfizer's (PFE) BLA for COVID-19 vaccine, Comirnaty. J&J (JNJ) released data supporting use of the booster shot.
Regeneron's (REGN) Wet AMD Study on High Dose Eylea Meets Goal
by Zacks Equity Research
Regeneron's (REGN) phase II study evaluating a higher 8-mg dose of Eylea injection in patients with wet age-related macular degeneration has met the primary safety endpoint.
Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study
by Zacks Equity Research
Novartis' (NVS) phase III study evaluating Kymriah for second-line treatment of patients with aggressive B-cell NHL fails to achieve primary endpoint of the study.
Bristol Myers (BMY) CAR T Cell Therapy Abecma Approved by EC
by Zacks Equity Research
Bristol Myers (BMY) wins EC approval for its CAR T cell immunotherapy, Abecma, for the treatment of multiple myeloma.